IL-17A MODULATORS AND THEIR USES

MX435207BActive Publication Date: 2026-06-12DICE ALPHA INC
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
MX · MX
Patent Type
Patents
Current Assignee / Owner
DICE ALPHA INC
Filing Date
2022-03-15
Publication Date
2026-06-12
Patent Text Reader

Abstract

This disclosure provides pharmaceutical compounds and compositions for IL-17A modulation useful for the treatment of inflammatory conditions, such as psoriasis.
Need to check novelty before this filing date? Find Prior Art

Claims

1. A compound represented by the structure of Formula I: or a pharmaceutically acceptable salt thereof, wherein: CA / is selected from an optionally substituted C3-12 carbocycle and an optionally substituted 3- to 12-membered heterocycle wherein one or more substituents on ring A are independently selected at each occurrence of: halogen, -OR11, -SR11, -N(R11)2, -C(O)R11, -C(O)N(R11)2, N(R11)C(O)R11, N(R11)S(O)2R11, -C(O)OR11, -OC(O)R11, -S(O)R11, -S(O)2R11, -NO2, =0, =S, =N(R11), -CN; and C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, each of which is optionally substituted with one or more independently selected halogen substituents, -OR11, -SR11, -N(R11)2, -C(O)R11, -C(O)N(R11)2, N(R11)C(O)R11, -C(O)OR11, -OC(O)R11, -S(O)R11, S(O)2R11, -NO2, =0, =S, =N(R11), -CN, C3-10 carbocycle and 3- to 10-membered heterocycle;wherein the C3-10 carbocycle and the 3-to-10-membered heterocycle are optionally substituted with one or more substituents selected from: halogen, -OR11, -N(R11)2, -C(O)R11, C(O)N(R11)2, N(R11)C(O)R11, -C(O)OR11, -OC(O)R11, -NO2, =0, =N(R11) and -CN; and C3-12 carbocycle and 3-to-12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from: halogen, -OR11, -SR11, -N(R11)2, -C(O)R11, -C(O)N(R11)2, N(R11)C(O)R11, -C(O)OR11, -OC(O)R11, -NO2, -CN, C1-6 alkyl and C1-6 haloalkyl; (b J is selected from an optionally substituted C3-10 carbocycle and an optionally substituted 3- to 12-membered heterocycle, wherein one or more substituents on ring B are independently selected at each occurrence of: 190 halogen, -OR12, -SR12, -N(R12)2, -C(O)R12, -C(O)N(R12)2, N(R12)C(O)R12 -C(O)OR12, OC(O)R12, -S(O)R12, -S(O)2R12, -NO2i =0, =S, =N(R12), -CN;and C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, each of which is optionally substituted with one or more independently selected halogen substituents, -OR12, -SR12, -N(R12)2, -C(O)R12, -C(O)N(R12)2, N(R12)C(O)R12 -C(O)OR12, -OC(O)R12, -S(O)R12, S(O)2R12, -NO2, =0, =S, =N(R12), -CN, C3-10 carbocycle and 3- to 10-membered heterocycle; wherein the C3-10 carbocycle and the 3- to 10-membered heterocycle are each optionally substituted with one or more substituents selected from: halogen, -OR12, -N(R12)2, -C(O)R12, C(O)N(R12)2, N(R12)C(O)R12-C(O)OR12, -OC(O)R12, -NO2, =0, =N(R11) and -CN; or R4 is selected from --C(O)N(R23)(R24) andp; where is an optionally substituted 4 to 9 member heterocycle where the optional substituents on are independently selected at each occurrence of: halogen, -OR13, -SR13, -N(R13)2, -C(O)R13, ​​-C(O)N(R13)2, -N(R13)C(O)R13 -C(O)OR13, OC(O)R13, ​​-S(O)R13, ​​-S(O)2R13, -NO2, =0, =S, =N(R13), -CN;and C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, each of which is optionally substituted with one or more independently selected halogen substituents, -OR13, -SR13, -N(R13)2, -C(O)R13, ​​-C(O)N(R13)2, N(R13)C(O)R13, ​​-C(O)OR13, -OC(O)R13, ​​-S(O)R13, ​​S(O)2R13, -NO2, =0, =S, =N(R13), -CN, C3-10 carbocycle and 3- to 10-membered heterocycle, wherein the C3-10 carbocycle and the 3- to 10-membered heterocycle are optionally substituted with one or more independently selected halogen substituents, -OR13, -N(R13)2, -C(O)R13, ​​-C(O)N(R13)2, N(R13)C(O)R13-C(O)OR13, -OC(O)R13, ​​-NO2, =0, =N(R13) and -CN; L is absent or selected from -O- and -NH-; RA is selected from hydrogen, halogen, -OR14, -N(R14)2, -C(O)R14, -C(O)N(R14)2, ' N(R14)C(O)R14 -C(O)OR14, -OC(O)R14, -NO2, -CN and C1-6 alkyl, wherein the C1-6 alkyl is optionally substituted with one or more substituents selected from: halogen, OR14, -N(R14)2, -C(O)R14, NO2, =0 and -CN;RB is selected from hydrogen, halogen, -OR15, -N(R15)2, -C(O)R15, -C(O)N(R15)2, ' N(R15)C(O)R15 -C(O)OR15, -OC(O)R15, -NO2, -CN and C1-6 alkyl, wherein the C1-6 alkyl is optionally substituted with one or more substituents selected from: halogen, OR15,N(R15)2, -C(O)R15, NO2, =0 and -CN, wherein at least one of RA or RB is not hydrogen; R' and R are independently selected from: 191 hydrogen, halogen, -OR1S and Ci-θ alkyl; wherein the C1-6 alkyl is optionally substituted with one or more substituents selected from: halogen, -OR16, -N(R16)2, -C(O)R16, -NO2j=0 and -CN; R1 is selected from -OR21, -N(R21)(R22), -N(R21)C(O)R22, -N(R21)C(O)OR22, N(R21)C(O)N(R21)(R22), -N(R21)S(=O)2N(R21)(R22) and -N(R21)S(=O)2(R22); each R2 and R3 is independently selected from: hydrogen, halogen, -OR17, C1-6 alkyl and C3-6 cycloalkyl;wherein the C1-6 alkyl and the C3-6 cycloalkyl are optionally substituted with one or more substituents selected from: halogen, -OR17, -N(R17)2, -C(O)R17, -NO2, =O and -CN; or R2 and R3 attached to the same carbon are joined to form a C3-6 cycloalkyl optionally substituted with one or more substituents selected from halogen, -OR17, -N(R17)2, -C(O)R17, NO2, =O and -CN; R21 is independently selected at each occurrence of hydrogen and Ci-Ce alkyl optionally substituted with one or more substituents independently selected from halogen, -OR17, -N(R17)2, -C(O)R17, -NO2, =O and -CN;R22 is selected from: C1-10 alkyl, C2-ium alkenyl, C2-ium alkynyl, each of which is optionally substituted with one or more independently selected halogen substituents, -OR18, -SR18, -N(R18)2, -C(O)R18, -C(O)N(R18)2, N(R18)C(O)R18, -C(O)OR18, -OC(O)R18, -S(O)R18, S(O)2R18, -NO2, =O, =S, =N(R18), -CN, C3-10 carbocycle, and 3- to 10-membered heterocycle; wherein the C3-10 carbocycle and the 3-to-10-membered heterocycle are optionally substituted with one or more substituents selected from: halogen, -OR18, -N(R18)2, -C(O)R18, C(O)N(R18)2, N(R18)C(O)R18, -C(O)OR18, -OC(O)R18, -NO2, =0, =N(R18) and -CN; and C3-i2 carbocycle and 3 to 12 membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from: halogen, -OR18, -SR18, -N(R18)2, -C(O)R18, -C(O)N(R18)2, N(R18)C(O)R18 -C(O)OR18, OC(O)R18, -S(O)R18, -S(O)2R18, -NO2, =0, =S, =N(R18), -CN;and alkyl of C1-10, alkenyl C2-10, alkynyl of C2-10, each of which is optionally substituted with one or more substituents selected independently of halogen, -OR18, -SR18, -N(R18)2, -C(O)R18, -C(O)N(R18)2, . N(R18)C(O)R18 -C(O)OR18, -OC(O)R18, -S(O)R18, S(O)2R18, -NO2, =0, =S, =N(R18), -CN, C3-10 carbocycle and 3- to 10-membered heterocycle; wherein the carbocycle of C3-10 and the 3- to 10-membered heterocycle are optionally substituted with one or more substituents selected from: halogen, -OR18,-N(R18)2, -C(O)R18, C(O)N(R18)2, N(R18)C(O)R18 -C(O)OR18,18; -OC(O)R18, -NO2, =0, =N(R18) and -CN; and 192 C3-10 carbocycles and 3- to 10-membered heterocycles, are each optionally substituted with one or more substituents selected from: halogen, -OR18,-N(R18)2, -C(O)R18, C(O)N(R18)2, N(R18)C(O)R18 -C(O)OR18, -OC(O)R18, -NO2, =0, =N(R18) and -CN;R23 is selected from: C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR19, -SR19, -N(R19)2, -NO2, -CN, C3-10 carbocycle and 3-to-10-membered heterocycle; wherein the C3-10 carbocycle and the 3-to-10-membered heterocycle are optionally substituted with one or more substituents selected from: halogen, OR19, -N(R19)2, =0, Ci-Ce alkyl, Ci-Ce haloalkyl and -CN; and C3-12 carbocycle and 3-to-12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR19, -N(R19)2, =0, Ci-Ce alkyl, Ci-Ce haloalkyl and -CN; R24 is selected from hydrogen and C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR19, -SR19, -N(R19)2, NO2, -CN, C3-6 carbocycle and 3- to 6-membered heterocycle;R11, R12, R13, R14, R15, R16, R17, R18, and R19 are independently selected at each occurrence of: hydrogen; and C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OH, Ci-Ce -O-alkyl, C1-C6-NH2 -O-haloalkyl, -NO2, =0, -CN, C3-10 carbocycle, and 3-to-10-membered heterocycle; wherein the C3-10 carbocycle and the 3-to-10-membered heterocycle are optionally substituted with one or more substituents selected from halogen, -OH, CrCe -O-alkyl, C1-C6-NH2 -O-haloalkyl, -NO2, =0, and -CN; and C3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents selected independently from: halogen, -OH, Ci-Ce -O-alkyl, Ci-Ce -O-haloalkyl, -NH2, -NO2, =0, -CN;and C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OH, -O-Ci-Ce alkyl, -O-Ci-Ce haloalkyl, -NH2, NO2, =0 and -CN; n is selected from O and 1; and m is selected from O, 1 and 2.

2. The compound or salt according to claim 1, characterized in that ring A is selected from an optionally substituted C3-C6 carbocycle, an optionally substituted 5- to 6-membered monocyclic heterocycle, and an optionally substituted 8- to 9-membered bicyclic heterocycle.

3. The compound or salt according to claim 1, characterized in that ring A is selected from optionally substituted cyclopropyl, optionally substituted cyclohexyl, optionally substituted phenyl, optionally substituted 5- to 6-membered heteroaryl, and optionally substituted 8- to 9-membered bicyclic heterocycle.

4. The compound or salt according to claim 1, characterized in that ring A is selected from cyclopropyl, cyclohexyl, phenyl, pyridine, pyrimidine, pyrazole, thiophene, indazole, tetrazole, oxadiazole, oxazole, isoxazole, imidazole, pyrrole, furan, benzothiophene, benzofuran, thieno[2,3-c]pyridine, thieno[2,3-d]pyridine, furo[3,2-c]pyridine, 4,6-dihydro[3,4-b]furan and benzodioxole, any of which is optionally substituted.

5. The compound or salt according to claim 1 to 4, characterized in that ring A is independently selected from: halogen, -OR11, -N(R11)2, N(R11)C(O)R11, -N(R11)S(O)2R11, -NO2, =0 and -CN; C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR11, -N(R11)2, N(R11)C(O)R11, -NO2, =0, -CN, C3-6 carbocycle and 3- to 6-membered heterocycle; wherein the C3-6 carbocycle and the 3- to 6-membered heterocycle are optionally substituted with one or more substituents selected from: halogen, -OR11, -N(R11)2, -NO2, =0, -CN; and C3-6 carbocycle and 3- to 6-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR11, -NO2, -CN, C1-6 alkyl and C1-6 haloalkyl.

6. The compound or salt according to any of claims 1 to 5, characterized in that n is 0.

7. The compound or salt in accordance with any of claims 1 to 5, characterized in that n is 1.

8. The compound or salt according to claim 6, characterized in that ring A is selected from an optionally substituted 5-membered monocyclic heterocycle and an optionally substituted 8- to 9-membered bicyclic heterocycle.

9. The compound or salt according to claim 8, characterized in that ring A is selected from an optionally substituted 5-membered monocyclic heteroaryl and an optionally substituted 8- to 9-membered bicyclic heterocycle.

10. The compound or salt according to claim 9, characterized in that the optionally substituted 5-membered monocyclic heteroaryl and the optionally substituted 8- to 9-membered bicyclic heterocycle QQRQbn / ZZnZ / q / YILI 194 comprise at least one heteroatom selected from nitrogen, oxygen, and sulfur.

11. The compound or salt according to claim 10, characterized in that the optionally substituted 5-membered monocyclic heteroaryl is selected from pyrazole, tetrazole, oxadiazole, isoxazole, pyrrole and furan, any of which is optionally substituted.

12. The compound or salt according to any of claims 8 to 11, characterized in that ring A is an optionally substituted 5-membered monocyclic heteroaryl, optionally substituted with one or more substituents selected independently from halogen, -OR11, -N(R11)2, -N(R11)S(O)2R11, -NO2, -CN, C1-6 alkyl, C3-5 carbocycle, C3-5 carbocycle and 3-to-5-membered heterocycle.

13. The compound or salt according to claim 11, characterized in that ring A is a 5-membered monocyclic heteroaryl substituted with a single substituent, wherein the single substituent is selected from halogen, -OR11, -N(R11)2, C(O)R11, -NO2, -CN, C1-6 alkyl, C3-5 carbocycle -alkyl, C3-5 carbocycle, and 3-to-5-membered heterocycloalkyl.

14. The compound or salt according to claim 13, characterized in that ring A is a 5-membered monocyclic heteroaryl substituted with a single substituent selected from -OR11, C1-6 alkyl, C3-5 carbocycle -alkyl, C3-5 carbocycle, 3-to-5-membered heterocycloalkyl, wherein R11 is selected from C1-6 alkyl.

15. The compound or salt according to claim 14, characterized in that ring A is selected from:

16. The compound or salt according to claim 8 or 12, characterized in that ring A is a 5-membered monocyclic heteroaryl substituted with one or more substituents independently selected from an optionally substituted C36 carbocycle and an optionally substituted 3- to 6-membered heterocycle. 195 17. The compound or salt according to claim 16, characterized QQRQbn / ZZnZ / q / YILI 18. The compound or salt according to any of claims 8 to 10, characterized in that ring A is an optionally substituted 8- to 9-membered heterocycle.

19. The compound or salt according to claim 18, characterized in that ring A is selected from a bicyclic ring, wherein the bicyclic ring is selected from an optionally substituted fused furan or an optionally substituted fused thiophene.

20. The compound or salt according to claim 19, characterized in that ring A is an 8- to 9-membered aromatic heterocycle.

21. The compound or salt according to claim 18, characterized in that ring A is selected from an optionally substituted bicyclic ring, wherein the bicyclic ring is a 5-6 fused ring system and the 5-membered ring contains no more than one nitrogen.

22. The compound or salt according to claim 18, characterized in that ring A is selected from an optionally substituted bicyclic ring, wherein the bicyclic ring is not selected from a fused pyrazole.

23. The compound or salt according to any of claims 18 to 22, characterized in that ring A is an 8- to 9-membered heterocycle optionally substituted with one or more substituents independently selected from halogen, -OR11, -NO2, -CN and C1-6 alkyl.

24. The compound or salt according to claim 18, characterized 25. The compound or salt according to claim 7, characterized in that each of R' and R" is independently selected from halogen, -OR16 and C1-6 alkyl optionally substituted with one or more substituents selected from halogen, -OR16, N(R16)2, -C(O)R16, -NO2, =0 and -CN.

26. The compound or salt according to claim 25, characterized in that each of R' and R are independently selected from fluorine and -OR16, wherein R16 is selected from optionally substituted C1-6 alkyl.

27. The compound or salt according to claim 26, characterized in that both R' and R" are fluorine.

28. The compound or salt according to any of claims 25 to 27, characterized in that ring A is selected from an optionally substituted C3-6 carbocycle, an optionally substituted 3- to 6-membered monocyclic heterocycle, and an optionally substituted 8- to 9-membered bicyclic heterocycle.

29. The compound or salt according to claim 28, characterized in that ring A is selected from C3-6 cycloalkyl, phenyl, 5- or 6-membered heteroaryl and 8- to 9-membered bicyclic heterocycle, any of which is optionally substituted.

30. The compound or salt according to claim 28, characterized in that ring A is selected from C3-6 cycloalkyl, phenyl, 5- or 6-membered heteroaryl, and 8- to 9-membered bicyclic heterocycle, wherein any of these is optionally substituted with one or more substituents independently selected from halogen, -OR11, -N(R11)2, -N(R11)S(O)2R11, -NO2, -CN, and C1-6 alkyl.

31. The compound or salt according to claim 28, characterized in that ring A is a C3-6 carbocycle optionally substituted with one or more substituents independently selected from: halogen, -OR11, -N(R11)2, -C(O)R11, -C(O)N(R11)2, 'N(R11)C(O)R11, -N(R11)S(O)2R11, -C(O)OR11, -OC(O)R11, -NO2 and -CN.

32. The compound or salt according to claim 28, characterized in that ring A is selected from unsubstituted cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.

33. The compound or salt according to claim 32, characterized in that it is selected from 34. The compound or salt according to claim 29, characterized in that ring A is phenyl substituted with one or more substituents.

35. The compound or salt according to claim 34, characterized in that ring A is phenyl with one or more substituents independently selected from -OR11, -N(R11)S(O)2R11 and -CN; wherein each R11 is independently selected from hydrogen and C1-6 alkyl.

36. The compound or salt according to claim 35, characterized 37. The compound or salt according to claim 29, characterized in that ring A is a 5- to 6-membered heteroaryl optionally substituted with one or more substituents independently selected from -OR11, -SR11, -N(R11)2, C(O)R11, -C(O)OR11, -OC(O)R11, -NO2, -CN; and C1-6 alkyl optionally substituted with one or more substituents independently selected from -OR11, -SR11, -N(R11)2, C(O)R11, -C(O)OR11, -OC(O)R11, -NO2, -CN, Casy carbocycle, and a 3- to 6-membered heterocycle.

38. The compound or salt according to claim 29, characterized in that ring A is a 5- to 6-membered heteroaryl substituted with one or more substituents independently selected from -OR11, -SR11, -N(R11)2, -C(O)R11, -C(O)OR11, -OC(O)R11, -NO2, -CN; and C1-6 alkyl optionally substituted with one or more substituents independently selected from -OR11, -SR11, -N(R11)2, -C(O)R11, -C(O)OR11, -OC(O)R11, -NO2, -CN, C3-6 carbocycle, and 3- to 6-membered heterocycle.

39. The compound or salt according to claim 38, characterized in that ring A is a pyridyl ring substituted with one or more substituents selected from -OR11, -SR11, -N(R11)2, -C(O)R11, -C(O)OR11, -OC(O)R11, -NO2 and -CN.

40. The compound or salt according to claim 37, characterized in that ring A is a 5- to 6-membered heteroaryl optionally substituted with one or more substituents independently selected from -OR11 and an optionally substituted C1,6 alkyl. 198 The compound or salt according to claim 40, characterized 41.

42. The compound or salt according to claim 29, characterized in that ring A is an 8- to 9-membered heterocycle optionally substituted with one or more substituents selected independently from: -OR11, -NO2, -CN; and C1-6 alkyl optionally substituted with one or more substituents selected independently from OR11, -NO2 and -CN.

43. The compound or salt according to claim 29, characterized in that ring A is an optionally substituted 9-membered bicyclic, wherein the optionally substituted 9-membered bicyclic is a fused 5-6 bicyclic ring system and the 6-membered ring does not contain heteroatoms.

44. The compound or salt according to claim 29, characterized in that ring A is an unsubstituted 8- to 9-membered bicyclic ring.

45. The compound or salt according to claim 44, characterized 46. ​​The compound or salt according to any of claims 1 to 45, characterized in that m is 0 and L is absent.

47. The compound or salt according to claim 46, characterized in that ring B is selected from an optionally substituted C3-8 monocyclic cycloalkyl and an optionally substituted 8- to 10-membered bicyclic carbocycle, wherein one or more substituents on ring B are independently selected at each occurrence from: halogen, -OR12, -NO2 and -CN; and optionally substituted C1-6 alkyl with one or more substituents independently selected from halogen, -OR12, -NO2, -NO2 and -CN.

48. The compound or salt according to claim 47, characterized in that ring B is a saturated C3-8 monocyclic cycloalkyl optionally substituted with one or more substituents selected independently of: halogen and C1-6 alkyl 199 optionally substituted with one or more substituents selected independently of halogen, -OR12 and -CN.

49. The compound or salt according to claim 48, characterized in that ring B is selected from cyclopentyl, cyclohexyl and cycloheptyl, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR12 and optionally substituted C1-3 alkyl.

50. The compound or salt according to claim 46, characterized in that ring B is cyclohexyl optionally substituted with one or more substituents independently selected from halogen, C1-3 alkyl and C1-3 haloalkyl.

51. The compound or salt according to claim 49, characterized in that ring B is selected from 52. The compound or salt according to claim 47, characterized in that ring B is a 9 or 10-membered bicyclic carbocycle optionally substituted.

53. The compound or salt according to claim 52, characterized in that ring B is an optionally substituted 9-membered bicyclic carbocycle selected from a 5-6 fused ring system and the optional substituents are independently selected from halogen, -OR12, C1-6 alkyl and C1-6 haloalkyl.

54. The compound or salt according to claim 53, characterized in that ring B is indane optionally substituted with one or more substituents selected independently from fluorine, chlorine, -OR12 and C1-6 alkyl optionally substituted with one or more substituents selected from halogen and -OR12.

55. The compound or salt according to claim 54, characterized in that ring B is selected from 56. The compound or salt according to any of claims 1 to 45, characterized in that m is 1.

57. The compound or salt according to claim 56, characterized in that L is absent.

58. The compound or salt according to claim 56, characterized in that L is -O-. 200 59. The compound or salt according to any of claims 56 to 58, characterized in that each R2 and R3 are independently selected from: hydrogen, halogen, -OR17, C1-6 alkyl and C3-6 cycloalkyl; wherein the C1-6 alkyl and the C3-6 cycloalkyl are optionally substituted with one or more substituents selected from: halogen, -OR17, -N(R17)2, -C(O)R17, -NO2, =O and -CN.

60. The compound or salt according to claim 59, characterized in that R2 and R3 are selected from -OR17 and C1-6 alkyl; wherein the C1-6 alkyl is optionally substituted with one or more substituents selected from: halogen, -OR17 and -CN.

61. The compound or salt according to claim 59, characterized in that at least one of the R2 and R3 is selected from -OR17 and C1-6 alkyl; wherein the C1-6 alkyl is optionally substituted with one or more substituents selected from: halogen, -OR17 and -CN.

62. The compound or salt according to claim 59, characterized in that R2 and R3 are each independently selected from hydrogen, C1-3 -O-alkyl and C1-3 alkyl optionally substituted with one or more substituents selected from C1-3 -O-alkyl.

63. The compound or salt according to any of claims 56 to 62, characterized in that ring B is selected from a C3-8 carbocycle each of which is optionally substituted with one or more substituents independently selected from fluorine, C1-3 alkyl, C1-3 haloalkyl and C1-3 alkoxy.

64. The compound or salt according to claim 63, characterized 65. The compound or salt according to any of claims 1 to 64, characterized in that RA is selected from hydrogen, fluorine, -OR14 and C1-6 alkyl 201 optionally substituted with one or more substituents selected from: halogen, -OR14, -NO2, =0 and -CN.

66. The compound or salt according to claim 65, characterized in that RA is selected from hydrogen and fluorine.

67. The compound or salt according to claim 66, characterized in that RA is fluorine.

68. The compound or salt according to any of claims 1 to 67, characterized in that RB is selected from hydrogen, -OR15 and C1-6 alkyl optionally substituted with one or more substituents selected from: halogen, -OR15, -NO2, =0 and -CN.

69. The compound or salt according to claim 68, characterized in that RB is selected from -OMe, -OEt, -CF3, -CHF2, -CH2F, methyl, ethyl, propyl and isopropyl.

70. The compound or salt according to claim 69, characterized in that RB is selected from methyl, ethyl, propyl and isopropyl.

71. The compound or salt according to claim 70, characterized in that RB is methyl.

72. The compound or salt according to any of claims 1 to 71, characterized in that R1 is selected from -N(R21)C(O)R22, -N(R21)C(O)OR22 and N(R21)C(O)N(R21)(R22).

73. The compound or salt according to any of claims 1 to 72, characterized in that R21 in each occurrence is selected from hydrogen and C1-C3 alkyl.

74. The compound or salt according to any of claims 1 to 72, characterized in that R21 in each occurrence is hydrogen.

75. The compound or salt according to any one of claims 1 to 74, characterized in that R22 is selected from: C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -C(O)OR18, -OR18 and C3-6 cycloalkyl; C3-6 cycloalkyl optionally substituted with halogen, -OR18, C1-6 alkyl and C1-6 haloalkyl; 3- to 6-membered monocyclic heterocycle optionally substituted with halogen, -OR18, C1-6 alkyl, C3-6 cycloalkyl, Cse-C1-6 cycloalkyl, C1-6 alkyl (3- to 6-membered heterocycloalkyl); and 8- to 10-membered bicyclic heterocycle optionally substituted with halogen, -OR18, C1-6 haloalkyl. QQRCbn / 77n7 / q / YILI 202 76. The compound or salt according to any of claims 1 to 74, characterized in that R22 is selected from: C1-4 alkyl optionally substituted with one or more substituents independently selected from halogen, -C(O)OR18 and C3-6 cycloalkyl; C3-6 cycloalkyl optionally substituted with halogen; 3- to 6-membered monocyclic heterocycle optionally substituted with -OR18, C1-6 alkyl, C3-6 cycloalkyl, Cs cycloalkyl, C1-6 alkyl, Ci-6-alkyl (3- to 6-membered heterocycloalkyl); and 8- to 10-membered bicyclic heterocycle.

77. The compound or salt according to any of claims 1 to 74, characterized in that R22 is selected from C1-4 alkyl optionally substituted with one or more substituents independently selected from halogen, -OR18, -SR18, -N(R18)2, C(O)R18, -C(O)OR18, -CN, C3-10 carbocycle and 3-to-10 membered heterocycle; wherein the C3-10 carbocycle and the 3-to-10 membered heterocycle are optionally substituted with one or more substituents selected from halogen, -OR18-NO2, =0 and -CN.

78. The compound or salt according to claim 77, characterized in that R22 is selected from C1-4 alkyl optionally substituted with one or two substituents independently selected from halogen, -OR18, -SR18, -N(R18)2, C(O)R18, -C(O)OR18, C3-10 carbocycle and 3-to-10-membered heterocycle; wherein the C3-10 carbocycle and the 3-to-10-membered heterocycle are each optionally substituted with one or more substituents selected from: halogen, -OR18 and -NO2.

79. The compound or salt according to claim 78, characterized in that R22 is selected from unsubstituted methyl, ethyl, propyl and isopropyl.

80. The compound or salt according to claim 78, characterized in that R22 is ethyl.

81. The compound or salt according to claim 77, characterized 203 QQRQbn / ZZnZ / q / YILI 82. The compound or salt according to any of claims 1 to 74, characterized in that R22 is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and phenyl, any of which is optionally substituted with one or more substituents independently selected from halogen and -OR18.

83. The compound or salt according to claim 82, characterized in that R22 is selected from cyclopropyl and cyclobutyl, each of which is optionally substituted with one or more fluorine.

84. The compound or salt according to claim 83, characterized in that R1 is selected from 85. The compound or salt according to any of claims 1 to 74, characterized in that R22 is selected from an optionally substituted 5- to 6-membered monocyclic heterocycle and an optionally substituted 8- to 10-membered bicyclic heterocycle, either of which comprises at least one heteroatom selected from nitrogen, oxygen, and sulfur.

86. The compound or salt according to claim 85, characterized in that R22 is selected from an optionally substituted saturated 5 or 6-membered monocyclic heterocycle.

87. The compound or salt according to claim 86, characterized in that R1 is selected from:

88. The compound or salt according to any one of claims 1 to 74, characterized in that R22 is selected from a 5- to 6-membered monocyclic heteroaryl optionally substituted with one or more substituents selected from: halogen, -OR18, -NO2, -CN; C1-6 alkyl being substituted with one or more substituents independently selected from -OR18, -SR18, -N(R18)2, -NO2, -O, -S, -N(R18), -CN, C3-6 carbocycle and 3- to 6-membered heterocycle; wherein the C3-6 carbocycle and the 3- to 6-membered heterocycle are each optionally substituted with one or more substituents selected from: halogen, -OR18, -NO2 and -CN; C3-6 carbocycle and the 3-to-6-membered heterocycle, each of which is optionally substituted with one or more substituents selected independently from: halogen, -OR18 and optionally substituted C1-3 alkyl.

89. The compound or salt according to claim 88, characterized in that R22 is selected from pyrazole and isoxazole substituted with one or more substituents selected from: halogen, -OR18 and -NO2; -C1 alkyl being substituted with one or more substituents independently selected from -OR18, -SR18, -N(R18)2, -NO2, -O, -S, -N(R18), -CN, C3-6 carbocycle and 3- to 6-membered heterocycle; wherein the C3-6 carbocycle and the 3- to 6-membered heterocycle are each optionally substituted with one or more substituents selected from: halogen, -OR18, -NO2 and -CN; -C2-6 alkyl that is optionally substituted with one or more substituents selected independently from -OR18, -SR18, -N(R18)2, -NO2, =O, =S, =N(R18), -CN, C3-6 carbocycle and the 3-to-6-membered heterocycle; wherein the C3-6 carbocycle and the 3-to-6-membered heterocycle are optionally substituted with one or more substituents selected from: halogen, -OR18, -NO2 and -CN;C3-6 carbocycle and the 3-to-6-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from: halogen, -OR18 and optionally substituted C1-3 alkyl.; 90. The compound or salt according to claim 88, characterized in that R22 is selected from pyrazole and isoxazole substituted with one or more substituents selected from: halogen, -OR18 and -NO2; C1-alkyl being substituted with one or more substituents independently selected from -OR18, -SR18, -N(R18)2, -NO2, -O, -S, -N(R18), -CN, C3-6 carbocycle and 3- to 6-membered heterocycle; wherein the C3-6 carbocycle and the 3- to 6-membered heterocycle are each optionally substituted with one or more substituents selected from: halogen, -OR18, -NO2 and -CN; and a C2-6 -alkyl that is optionally substituted with one or more substituents selected independently from -OR18, -SR18, -N(R18)2, -NO2, =0, =S, =N(R18), -CN, a C3-6 carbocycle and a 3-to-6-membered heterocycle; wherein the C3-6 carbocycle and the 3-to-6-membered heterocycle are optionally substituted with one or more substituents selected from: halogen, -OR18, -NO2 and -CN.

91. The compound or salt according to claim 88, characterized 92. The compound or salt according to claim 88, characterized in that R22 is selected from 1,2,3-diadiazole, isothiazole, thiazole and thiophene, any of which is optionally substituted.

93. The compound or salt according to claim 88, characterized in that R22 is a 6-membered heteroaryl with one or more substituents independently selected from -OR18, C1-6 alkyl optionally substituted with one or more substituents selected from -OR18, C3-6 carbocycle optionally substituted, and 3-to-6-membered heterocycle optionally substituted.

94. The compound or salt according to claim 93, characterized in that R22 is pyridine optionally substituted with one or more substituents selected from -OR18 and C1-6 alkyl optionally substituted with one or more substituents selected from -OR18.

95. The compound or salt according to claim 94, characterized in that R1 is 96. The compound or salt according to any of claims 1 to 74, characterized in that R1 is -N(R21)S(=O)2(R22) or -N(R21)S(=O)2N(R21)(R22) and R22 is C1-6 2O6 alkyl or C3-6 cycloalkyl, either of which is optionally substituted with one or more independently selected halogen substituents, -OR18, -NO2, =O and -CN.

97. The compound or salt according to claim 96, characterized Λ z N 'h because R1 is Η u 98. The compound or salt according to any one of claims 1 to 97, characterized in that R4 is -C(O)N(R23)(R24) and R23 is C1-6 alkyl optionally substituted with one or more substituents independently selected from halogen, -O C1-6 alkyl, Ci-6 haloalkyl, -NO2, -CN, C3-10 carbocycle and 3 to 10 membered heterocycle; wherein the C3-10 carbocycle and the 3 to 10 membered heterocycle are optionally substituted with one or more substituents selected from: halogen, -OR19, N(R19)2, =0, Ci-Ce alkyl, Ci-Ce haloalkyl and -CN; optionally substituted C3-6 carbocycle and optionally substituted 3 to 6 membered heterocycle.

99. The compound or salt according to claim 98, characterized in that R24 is hydrogen.

100. The compound or salt according to claim 99, characterized in that R4 is selected from:

101. The compound or salt according to any of claims 1 to Y (Y 97, characterized in that R4 is YY, is selected from an optionally substituted saturated 4 or 8 member heterocycle.

102. The compound or salt according to claim 101, characterized in that the optionally substituted saturated 4- to 8-membered heterocycle is an optionally substituted 4- to 6-membered heterocycle with one or more substituents independently selected from: halogen, -OR13, -N(R13)2, -C(O)R13, ​​-C(O)N(R13)2, N(R13)C(O)R13, ​​-C(O)OR13, -OC(O)R13, ​​S(O)R13, ​​-NO2, =O, =S, =N(R13), -CN; and C1-10 alkyl optionally substituted with one or more halogen substituents selected, -OR13, -C(O)R13 -C(O)OR13, -N(R13)2, -NO2, =0, -CN, C3-10 carbocycle and wherein the C3-10 carbocycle is optionally substituted with one or more halogen substituents selected, -OR13,-N(R13)2, -C(O)R13, ​​-C(O)N(R13)2, N(R13)C(O)R13 -C(O)OR13, -OC(O)R13, ​​NO2, =0, =N(R13) and -CN.

103. The compound or salt according to claim 101, characterized in that when R4 is A and J it is selected from azetidine, piperidine, piperazine, morpholine, thiomorpholine, thiomorpholine 1,1-dioxide and azaspiro[3.3]heptane any of which is optionally substituted.

104. The compound or salt according to claim 103, characterized in that when R4 is Y—A it is selected from azetidine, piperidine, piperazine, morpholine, thiomorpholine and thiomorpholine 1,1-dioxide any of which is optionally substituted.

105. The compound or salt according to claim 101, characterized 208 106. The compound or salt according to any of claims 1 to 105, characterized in that the compound of Formula (I) is represented by Formula (IA):

107. The compound or salt according to any of claims 1 to 105, characterized in that the compound of Formula (I) is represented by Formula (IB):

108. The compound or salt according to any of claims 1 to 105, characterized in that the compound of Formula (I) is represented by Formula (IC): 209 Rb wherein R2 is independently selected from -OR17, C1-6 alkyl and C3-6 cycloalkyl; wherein the C1-6 alkyl and the C3-6 cycloalkyl are optionally substituted with one or more substituents selected from: halogen, -OR17, -N(R17)2, -C(O)R17, -NO2, =0 and -CN.

109. The compound or salt according to any of claims 1 to 105, characterized in that the compound of Formula (I) is represented by Formula (ID):

110. The compound or salt according to any of claims 1 to 109, characterized in that Formula (I) is selected from a pICso compound of A and B.

111. The compound or salt according to any of claims 1 to 109, characterized in that Formula (I) is selected from a pICso compound of A.

112. A pharmaceutical composition comprising the compound according to any one of claims 1 to 108 and a pharmaceutically acceptable excipient.

113. A method for modulating IL-17A in a subject in need thereof, characterized in that it comprises administering to said subject a compound according to any of claims 1 to 109 or a pharmaceutical composition according to claim 112.

114. A method of treating an inflammatory disease or condition, characterized in that it comprises administering to a subject in need thereof a compound or salt in accordance with any of claims 1 to 109.

115. The method according to claim 14, characterized in that the inflammatory disease or condition is selected from plaque psoriasis, guttate psoriasis, inverse psoriasis, pustular psoriasis, erythrodermic psoriasis, psoriatic arthritis, ankylosing spondylitis, hidradenitis suppurativa, rheumatoid arthritis, palmoplantar psoriasis, spondyloarthritis, and non-infectious uveitis.